Diagnostic and prognostic role of LINC01767 in hepatocellular carcinoma

Table 1 univariate overall survival analysis and disease-free survival analysis in hepatocellular carcinoma

Variable	Number	Event/total	MST months	P value	Number	Event/total	MST months	P value
DFS					OS
Gender				0.429				0.227
Male	208	116/208	21.55 (17.64-33.05)		233	74	81.67 (53.29-NA)
Female	90	57/90	18.59 (14.85-35.84)		109	49	48.95 (37.29-80.68)
Age				0.644				0.488
≤ 40	25	17/25	12.91 (8.61-NA)		29	9	NA (20.11-NA)
40-60	113	61/113	25.3 (14.85-67.58)		128	44	69.51 (40.37-NA)
> 60	100	55/100	24.77 (18.59-47.04)		1113	35	80.68 (55.35-NA)
> 70	52	35/52	21.16 (14.59-33.05)		64	34	45.53 (33.02-70.01)
Race				0.145				0.392
White	146	96	19.19 (14.956-23.424)		168	71	5.117 (35.861-55.919)
Asian	133	69	27.2 (4.977-49.423)		148	42	NA
Black	11	4	67.58 (NA)		15	5	16.286 (5.829-69.671)
BMI				0.029a				0.008a
< 18.5	16	9	13.07 (9.13-NA)		19	6	107.03 (20.8-NA)
18.2-23	77	50	12.84 (9.49-29.66)		89	40	35.74 (22.77-NA)
23-25	49	22	50.03 (21.16-NA)		55	12	81.67 (81.67-NA)
25-30	78	40	21.62 (16.13-NA)		88	28	70.01 (37.68-NA)
> 30	57	36	25.3 (15.7-NA)		64	20	69.51 (45.89-NA)
Gene expression				0.711				0.016a
High	133	72	28.88 (19.45-47.73)		168	103	53.29 (39.75-107.03)
Low	132	67	16.49 (13.07-23.62)		167	122	69.51 (51.25-NA)
Family history of cancer				0.515				0.439
Yes	91	53	18.33 (13.14-37.12)		104	39	69.51 (43.47-95.55)
No	168	99	23.95 (18.59-35.58)		194	71	55.65 (33.384-77.916)
Risks of HCC				0.724				0.007a
No	60	35	18.59 (12.514-24.66)		83	44	33.02 (23.447 42.593)
Yes	219	125	23.030 (16.229-29.831)		241	73	80.68 (50.109-111.251)
AFP				0.736				0.698
< 400 ng/mL	183	99	27.2 (20.99-36.7)		199	56	80.68 (55.35-NA)
≥ 400 ng/mL	51	29	15.7 (8.64-NA)		61	21	81.67 (33.02-NA)
CHIl-phu grade				0.658				0.220
A	187	101	23.03 (18.59-42.04)		204	52	102.66 (70.01-NA)
B	17	10	23.95 (8.64-NA)		20	8	33.02 (19.74-NA)
C	1	1	35.58 (NA-NA)		1	1	53.35 (NA-NA)
Surgery				0.0001a				< 0.0001a
1	121	79	13.14 (9.72-19.25)		129	48	39.75 (30.58-NA)
2	18	12	15.41 (6.24-NA)		25	14	37.29 (17.58)
3	75	34	47.04 (28.8-71.06)		81	13	81.67 (69.51)
4	68	39	29.96 (18.33-71.91)		79	32	70.01 (46.75)
5	1	0	NA (NA-NA)		1	0	NA (NA-NA)
6	15	9	19.65 (8.28-NA)		25	14	19.58 (4.24-NA)
Tumor histological grade				0.656				0.693
G1	47	25	29.66 (19.45-73.62)		53	17	69.51 (46.75-NA)
G2	138	80	20.99 (16.36-28.88)		161	58	55.65 (41.75-NA)
G3	99	59	15.74 (12.61-47.04)		111	39	53.29 (45.07-NA)
G4	10	5	7.36 (4.17-NA)		12	5	NA (13.47-NA)
T-stage				< 0.0001a				< 0.0001a
T1	151	65	42.02 (33.06-71.06)		168	41	80.68 (69.51-NA)
T2	73	49	15.7 (11.17-23.62)		84	28	60.84 (37.75-NA)
T3	62	49	9.94 (8.54-14.85)		74	43	25.3 (18.27-58.84)
T4	9	8	7.85 (5.91-NA)		13	10	18.33 (8.94-NA)
Lymph node status				0.357				0.033a
Negative	211	118	23.03 (16.49-40.37)		239	2	83.51 (60.84-NA)
Positive	3	2	8.64 (6.6-NA)		3	77	33.02 (9.86-NA)
X	84	53	14.13-28.88		99	43	37.68 (27.5-55.65)
Margin				0.0806	302	104	69.51 (53.29-102.66)	0.0002a
R0	270	154	21.62		15	8	37.29 (27.5-NA)
R1	13	11	15.6		1	1	7.33 (NA-NA)
Vascular invasion				0.0004a				0.0326a
Negative	164	77	35.84 (28.88-67.58)		187	54	80.68 (55.65-NA)
Positive	73	47	13.63 (10.81-24.77)		27	27	81.67 (45.89-NA)
NA	13	9	8.74 (4.14-NA)		8	8	48.95 (13.96-NA)
Adjacent hepatic tissue inflammation				0.3787				0.772
No	100	56	23.95 (18.59-40.37)		112	35	80.68 (55.65-NA)
Mild	86	48	21.55 (18.17-53.55)		93	25	NA (45.53-NA)
Severe	15	10	18.33 (9.72-NA)		17	5	NA (35.74-NA)
Stage				< 0.0001a				< 0.0001a
1	145	62	40.37 (29.96-71.91)		161	37	83.18 (70.01-NA)
2	66	43	18.17 (9.72-29.3)		77	24	60.84 (45.53-NA)
3	67	52	9.76 (8.34-14.22)		80	45	25.3 (20.11-58.84)
4	2	2	7.49 (5.49-NA)		3	3	18.33 (7.33-NA)

^aP < 0.05.

DFS: Disease free survival; OS: Overall survival; MST: Mean survival time; NA: Not available; BMI: Body mass index; HCC: Hepatocellular carcinoma.

Table 2 Multivariate overall survival disease-free survival analysis in hepatocellular carcinoma

Characteristics	Beta	HR	95%CI	P value
Pathologic T stage
T1		Reference
T2	0.085	1.089	0.455-2.603	0.848
T3	0.608	1.838	0.857-3.943	0.118
T4	0.364	1.440	0.1684-12.317	0.739
Pathologic N stage
N0		Reference
N1	1.413	4.108	0.528-31.958	0.177
Pathologic M stage
M0		Reference
M1	1.580	4.855	0.378-62.357	0.225
BMI
≤ 25		Reference
> 25	-0.013	0.987	0.532-1.830	0.966
Residual tumor
R0		Reference
R1	0.289	1.334	0.172-10.360	0.782
R2	0.0602	1.062	0.0340-33.231	0.972
Vascular invasion
No		Reference
Yes	0.556	1.743	0.829-3.664	0.143
LINC01767
Low		Reference
High	0.642	1.89944998718678	1.006-3.585	0.048a

^aP < 0.05.

BMI: Body mass index; HR: Hazard ratio; CI: Confidence interval.